Lattice Biologics (TSX: V.LBL) is a biotech venture working in the field of cellular therapies and tissue engineering with a focus on bone, skin and cartilage regeneration. Its Extracelluar Matrix Technology has made Lattice an emerging leader in the sector as it develops and processes biologic allograft products for both domestic and international markets. More recently the company has expanded its portfolio and through the use of its ECM technology is developing a disruptive cancer diagnostic technique that is sure to revolutionize the way oncologists treat their patients. I’m Gaalen Engen, head of Editorial at Stockhouse Publishing, have a listen as I speak with Lattice Biologics CEO, Guy Cook, to get a better understanding of the company and the potential it holds.
April 27, 2016